MILREM-ROBOTICS
12.1.2021 08:02:41 CET | Business Wire | Press release
The medium class Type-X Robotic Combat Vehicle by the European leading robotics and autonomous systems developer Milrem Robotics passed its initial mobility tests.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005487/en/
The Type-X will become an intelligent wingman to main battle tanks and infantry fighting vehicles and will be capable of taking on the most dangerous tasks and positions, resulting in lower lethality risks.
“The Type-X will provide equal or overmatching firepower and tactical usage to a unit equipped with Infantry Fighting vehicles. It provides means to breach enemy defensive positions with minimal risk for own troops and replacing a lost RCV is purely a logistical nuance,” said Kuldar Väärsi, CEO of Milrem Robotics.
The Type-X can be fitted with a cannon up to 50 mm. With up to a 30 mm cannon the RCV is airdroppable - the C-130J and the KC-390 can carry one, an A400M two and a C-17 five.
“The vehicle will be equipped with intelligent functions such as follow-me, waypoint navigation and obstacle detection with Artificial Intelligence being part of the algorithms,” Väärsi said. “Also, our software developers have taken a totally new and innovative approach to allow remote controlled operations on higher speeds.”
With a weight of 12 tons and efficient power management the vehicle has superior terrain capabilities. Its height of 2.2 m and a rear engine provide low visual and heat signature.
The Type-X is three to four times lighter and its cost significantly lower than that of a conventional IFV. It has been designed with intelligent predictive maintenance combined with a Health and Usage Monitoring System and Line Replacement Unit principle to ensure a low Through Lifecycle Cost and logistic footprint. Its hybrid powertrain and rubber tracks reduce lifecycle costs significantly.
To create the Type-X Milrem Robotics utilized its knowledge gained from developing its THeMIS Unmanned Ground Vehicle, intended to support dismounted troops, that has been acquired by ten countries, including seven NATO members: France, Norway, the UK, the US, Germany, the Netherlands and Estonia.
Milrem Robotics is the European leading robotics and autonomous systems developer with two offices in Estonia, one in Sweden and Finland and shortly one in the Netherlands.
The company leads a consortium that was awarded 30,6 MEUR from the European Commission’s European Defence Industrial Development Programme (EDIDP) to develop a European standardized unmanned ground system.
Watch the Type-X video: https://youtu.be/34-NWYQ0L0c
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005487/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Boyd Watterson Global Names John Creswell Global Chief Client Officer to Accelerate Global Growth and Client Engagement23.7.2026 15:00:00 CEST | Press release
Veteran investment management executive will lead global sales, client engagement and marketing as Boyd Watterson Global continues expanding its global alternatives platform across real estate, infrastructure, and debt strategies. Boyd Watterson Global today announced the appointment of John Creswell as Global Chief Client Officer, a newly created senior leadership role that reflects the firm's continued investment in growth and its evolution into a leading global alternatives investment platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722823117/en/ John Creswell has joined Boyd Watterson Global as Global Chief Client Officer, a newly created role overseeing global sales, client engagement and marketing across the U.S., Europe and APAC. In this role, Creswell will oversee global sales, client engagement and marketing efforts across the United States, Europe and APAC, helping investors access the firm's capabilitie
Trulioo Launches AI Agent to Resolve Beneficial Ownership Where Global Registries Fall Short23.7.2026 15:00:00 CEST | Press release
Breakthrough AI agent reconstructs ownership for long-tail businesses and hard-to-reach jurisdictions while significantly increasing UBO coverage Trulioo, a global risk intelligence platform, today announced the UBO Discovery Agent, the newest layer in Trulioo's UBO Discovery capability inside its business risk and Know Your Business (KYB) verification workflow. AI is reshaping fraud, making it easier for bad actors to hide, and harder for companies to catch them. This makes the already tough job of verifying who actually owns a business even more difficult. Determining a business's ultimate beneficial owner is an ongoing, acute challenge for companies: registry coverage is inconsistent across countries, and even where registries exist, they typically record shareholders and directors of record (rather than the people actually in control). That data isn't simply outdated, it reflects a structural lag: ownership changes and time passes before the filing is made and processed, so a looku
Humanoid Raises $152 Million at $1.35 Billion Post-Money Valuation, Becoming Europe's First Pure-Play Humanoid Robotics Unicorn23.7.2026 15:00:00 CEST | Press release
Humanoid announces its Series A investment round, reaching a $1.35 billion valuation just two years after founding.It is the largest ever Series A for a humanoid-first robotics company in Europe, positioning Humanoid as the leading humanoid-first robotics unicorn in the UK and continental Europe.The new capital will accelerate Humanoid's next-generation robot development, commercial deployments with global industrial leaders, and evolution of the proprietary AI platform on the path toward general-purpose humanoids.The investment marks a defining moment for Europe's tech ecosystem, showing that globally competitive Physical AI companies can be built and scaled in Europe. Humanoid, a UK-based AI and robotics company building industrial humanoid robots, announced a $152 million Series A financing at a $1.35 billion post-money valuation. This funding brings the total amount raised to date to $270 million. The round was led by Prime Movers Lab, a venture capital firm focused on investments
Riskified Named to the CNBC World's Top Fintech Companies 2026 List23.7.2026 14:00:00 CEST | Press release
Payment category recognition marks Riskified's continued presence among the world's leading fintech innovators Riskified (NYSE: RSKD), a global leader in ecommerce fraud detection and risk intelligence, has been named to CNBC's World's Top Fintech Companies 2026 list, in the Payments category. The list, now in its fourth edition, is produced by CNBC in partnership with Statista Inc., the global statistics and industry ranking firm. It was announced on July 22, 2026, and is available on CNBC's website. This is Riskified's second time making the list. The company previously earned this recognition in 2024, reinforcing its position in the ecommerce fraud and risk intelligence sector and underscoring its ongoing success in empowering businesses to grow revenue and profitability by mitigating risk through its AI-powered platform. CNBC and Statista's ranking covers the top 500 companies across eight fintech segments — Payments, Neobanking, Alternative Financing, Wealth Technology, Digital As
Azafaros Completes Enrollment of Phase 3 (NAVIGATE) Study Evaluating Nizubaglustat for the Treatment of Patients with GM1/GM2 Gangliosidoses23.7.2026 13:00:00 CEST | Press release
NAVIGATE comprises two pivotal Phase 3 studies investigating nizubaglustatRecruitment completed in Phase 3 registrational study in patients with late-infantile and juvenile GM1/GM2 gangliosidosesEnrollment in Niemann-Pick type C disease (NPC) Phase 3 study is ongoingTopline data from GM1/GM2 gangliosidoses Phase 3 study is anticipated in early 2028 Azafaros, a private company building a portfolio of disease-modifying therapeuticsto become a leader in lysosomal storage disorders (LSDs) focused on addressing neurological symptoms, today announced the completion of patient recruitment in its Phase 3 study evaluating nizubaglustat for the treatment of GM1/GM2 gangliosidoses. “Completing enrollment in our Phase 3 GM1/GM2 study is a significant step toward potentially bringing nizubaglustat to patients and families living with these devastating neurodegenerative diseases," said Stefano Portolano, Chief Executive Officer at Azafaros. "We are deeply grateful to the patients, caregivers, invest
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom